Plasma proteome profiles treatment efficacy of incretin dual agonism in diet‐induced obese female and male mice

Unimolecular peptides targeting the receptors for glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) (GLP‐1/GIP co‐agonist) have been shown to outperform each single peptide in the treatment of obesity and cardiometabolic disease in preclinical and clinical trials. By combining physiological treatment endpoints with plasma proteomic profiling (PPP), we aimed to identify biomarkers to advance non‐invasive metabolic monitoring of compound treatment success and exploration of ulterior treatment effects on an individual basis.

[1]  M. Tschöp,et al.  Insights into incretin-based therapies for treatment of diabetic dyslipidemia. , 2020, Advanced drug delivery reviews.

[2]  K. Duffin,et al.  Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes , 2020, Diabetes Care.

[3]  Philipp E. Geyer,et al.  Multiparametric Assays for Accelerating Early Drug Discovery. , 2020, Trends in pharmacological sciences.

[4]  M. Coghlan,et al.  How May GIP Enhance the Therapeutic Efficacy of GLP-1? , 2020, Trends in Endocrinology & Metabolism.

[5]  S. Fishman,et al.  Incretin Hormones in the Control of Immunometabolism , 2019, Immunometabolism.

[6]  Philipp E. Geyer,et al.  Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease , 2019, Molecular systems biology.

[7]  Matthias Mann,et al.  Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery. , 2018, Cell systems.

[8]  Matthias Mann,et al.  Plasma Proteome Profiling to detect and avoid sample‐related biases in biomarker studies , 2018, bioRxiv.

[9]  L. Trouw,et al.  Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population , 2018, Front. Immunol..

[10]  R. Gimeno,et al.  Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial , 2018, The Lancet.

[11]  S. Lim,et al.  Association of circulating proinflammatory marker, leucine‐rich‐α2‐glycoprotein (LRG1), following metabolic/bariatric surgery , 2018, Diabetes/metabolism research and reviews.

[12]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[13]  J. Pankow,et al.  Hepatocyte growth factor is associated with progression of atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA). , 2018, Atherosclerosis.

[14]  Xian-cheng Jiang,et al.  Phospholipid transfer protein: its impact on lipoprotein homeostasis and atherosclerosis , 2018, Journal of Lipid Research.

[15]  Matthias Mann,et al.  Revisiting biomarker discovery by plasma proteomics , 2017, Molecular systems biology.

[16]  M. Tschöp,et al.  The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. , 2017, Cell metabolism.

[17]  G. Watts,et al.  Novel protein biomarkers associated with coronary artery disease in statin-treated patients with familial hypercholesterolemia. , 2017, Journal of clinical lipidology.

[18]  Dongling Yang,et al.  Macrophagic CD146 promotes foam cell formation and retention during atherosclerosis , 2017, Cell Research.

[19]  A. Kelly,et al.  Cardiovascular effects of bariatric surgery , 2016, Nature Reviews Cardiology.

[20]  C. Aguilar-Salinas,et al.  The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. , 2016, Metabolism: clinical and experimental.

[21]  M. Daha,et al.  Sex matters: Systemic complement activity of female C57BL/6J and BALB/cJ mice is limited by serum terminal pathway components. , 2016, Molecular immunology.

[22]  Marco Y. Hein,et al.  The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.

[23]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[24]  J. Holst,et al.  The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss , 2016, Nutrition & Diabetes.

[25]  Matthias Mann,et al.  Plasma Proteome Profiling to Assess Human Health and Disease. , 2016, Cell systems.

[26]  M. Jauhiainen,et al.  The role of ANGPTL3 in controlling lipoprotein metabolism , 2016, Endocrine.

[27]  A. Shimatsu,et al.  Thrombospondin 1 as a novel biological marker of obesity and metabolic syndrome. , 2015, Metabolism: clinical and experimental.

[28]  N. Roher,et al.  AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease , 2015, Journal of leukocyte biology.

[29]  Marie-Liesse Asselin-Labat,et al.  Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses , 2015, Nucleic acids research.

[30]  S. Horgan,et al.  Benefits of bariatric surgery do not reach obese men. , 2014, Journal of laparoendoscopic & advanced surgical techniques. Part A.

[31]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[32]  Weston R. Spivia,et al.  Complement protein C1q promotes macrophage anti-inflammatory M2-like polarization during the clearance of atherogenic lipoproteins , 2014, Inflammation Research.

[33]  D. Allison,et al.  Variations in body weight, food intake and body composition after long-term high-fat diet feeding in C57BL/6J Mice , 2014, Obesity.

[34]  D. Levy,et al.  Protein Biomarkers of New-Onset Cardiovascular Disease: Prospective Study From the Systems Approach to Biomarker Research in Cardiovascular Disease Initiative , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[35]  J. Holst,et al.  Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. , 2014, The lancet. Diabetes & endocrinology.

[36]  Bin Yang,et al.  Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans , 2013, Science Translational Medicine.

[37]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[38]  Joachim Spranger,et al.  Sexual Dimorphic Regulation of Body Weight Dynamics and Adipose Tissue Lipolysis , 2012, PloS one.

[39]  A. Rissanen,et al.  Obesity‐Related Derangements of Coagulation and Fibrinolysis: A Study of Obesity‐Discordant Monozygotic Twin Pairs , 2012, Obesity.

[40]  S. Stepaniants,et al.  A Gene Expression Signature That Classifies Human Atherosclerotic Plaque by Relative Inflammation Status , 2011, Circulation. Cardiovascular genetics.

[41]  T. Nakayama,et al.  Inflammation, a Link between Obesity and Cardiovascular Disease , 2010, Mediators of inflammation.

[42]  G. Koh,et al.  Adipocytokine Orosomucoid Integrates Inflammatory and Metabolic Signals to Preserve Energy Homeostasis by Resolving Immoderate Inflammation* , 2010, The Journal of Biological Chemistry.

[43]  N. Lundbom,et al.  Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. , 2009, Gastroenterology.

[44]  M. Tschöp,et al.  Defective Lipid Delivery Modulates Glucose Tolerance and Metabolic Response to Diet in Apolipoprotein E–Deficient Mice , 2008, Diabetes.

[45]  J. Liao,et al.  Differential Association of Hemoglobin with Proinflammatory High Density Lipoproteins in Atherogenic/Hyperlipidemic Mice , 2007, Journal of Biological Chemistry.

[46]  P. Stopka,et al.  Species-specific Expression of Major Urinary Proteins in the House Mice (Mus musculus musculus and Mus musculus domesticus) , 2007, Journal of Chemical Ecology.

[47]  V. Cuomo,et al.  Gender differences in drug responses. , 2007, Pharmacological research.

[48]  L. Gaal,et al.  Obesity, haemostasis and the fibrinolytic system , 2002, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[49]  K. O’Brien,et al.  Glycosylphosphatidylinositol-specific phospholipase D is expressed by macrophages in human atherosclerosis and colocalizes with oxidation epitopes. , 1999, Circulation.

[50]  R. Mann,et al.  Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. , 1998, British journal of clinical pharmacology.

[51]  Elazer R. Edelman,et al.  Adv. Drug Delivery Rev. , 1997 .

[52]  R. Langer,et al.  Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma , 2014, Histochemistry and Cell Biology.

[53]  M. Szklo,et al.  The Multi-Ethnic Study of Atherosclerosis (MESA) , 2012 .